Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial

JAMA Oncology

Volumn 4, Issue 5, 2018, Pages

  Fuchs, Charles S ^a   Doi, Toshihiko ^b   Jang, Raymond W ^c,d   Muro, Kei ^e   Satoh, Taroh ^f   Machado, Manuela ^g   Sun, Weijing ^h,i   Jalal, Shadia I ^j   Shah, Manish A ^k   Metges, Jean Phillipe ^l   Garrido, Marcelo ^m   Golan, Talia ^n,o   Mandala, Mario ^p   Wainberg, Zev A ^q   Catenacci, Daniel V ^r   Ohtsu, Atsushi ^b   Shitara, Kohei ^b   Geva, Ravit ^o   Bleeker, Jonathan ^s   Ko, Andrew H ^t   Ku, Geoffrey ^u   Philip, Philip ^v   Enzinger, Peter C ^w   Bang, Yung Jue ^x   Levitan, Diane ^y   Wang, Jiangdian ^y   Rosales, Minori ^y   Dalal, Rita P ^y   Yoon, Harry H ^z   more..

^a YALE CANCER CENTER   (United States)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^h UNIVERSITY OF PITTSBURGH   (United States)

ⁱ UNIVERSITY OF KANSAS   (United States)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^l BREST UNIVERSITY HOSPITAL   (France)

^m PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

ⁿ SHEBA MEDICAL CENTER   (Israel)

^o TEL AVIV UNIVERSITY   (Israel)

^p PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^s SANFORD RESEARCH   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^v KARMANOS CANCER INSTITUTE   (United States)

^w HARVARD MEDICAL SCHOOL   (United States)

^x Seoul National University College of Medicine   (South Korea)

^y MERCK RESEARCH LABORATORIES   (United States)

^z MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUOROPYRIMIDINE; PEMBROLIZUMAB; PLATINUM; PROGRAMMED DEATH 1 LIGAND 1; TRASTUZUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER;

ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER GROWTH; CANCER PATIENT; CARDIOMYOPATHY; CAUCASIAN; CHOLESTASIS; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FATIGUE; FEMALE; FOLLOW UP; GASTROESOPHAGEAL JUNCTION; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PATIENT DECISION MAKING; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRACTICE GUIDELINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; STEVENS JOHNSON SYNDROME; STOMACH CANCER; TIME FACTOR; TREATMENT RESPONSE; CLINICAL TRIAL; ESOPHAGUS TUMOR; KAPLAN MEIER METHOD; MICROSATELLITE INSTABILITY; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOMARKERS, TUMOR; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; STOMACH NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85047499076     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2018.0013     Document Type: Article

References (41)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
4. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;(3):CD004064.
5. Lordick F, Shitara K, Janjigian YY. New agents on the horizon in gastric cancer. Ann Oncol. 2017;28 (8):1767-1775.
6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): gastric cancer (version 5.2017). 2017. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed December 5, 2017.
7. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38-v49.
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): esophageal and esophagogastric junction cancers (version 4.2107). 2017. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed December 5, 2017.
9. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517): 202-209.
10. Abdel-Rahman O. Immune checkpoints aberrations and gastric cancer: assessment of prognostic value and evaluation of therapeutic potentials. Crit Rev Oncol Hematol. 2016;97:65-71.
11. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7): 1027-1034.
12. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717-726.
13. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92(3):205-216.
15. National Cancer Institute. Common terminology criteria for adverse events v4.0 (CTCAE). 2009. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed December 5, 2017.
16. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika. 1934;26:404-413.
17. Wallden B, Pekker I, Popa S, et al. Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System. J Clin Oncol. 2016;34(15) (suppl):3034.
18. Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127 (8):2930-2940.
19. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908-918.
20. Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21): 2460-2467.
21. Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7): 976-983.
22. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-1550.
23. Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18(2):212-220.
24. Hamid O, Robert C, Ribas A, et al. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). J Clin Oncol. 2014;32(15)(suppl): 3000.
25. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956-965.
26. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(15):2306-2314.
27. Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13): 1513-1518.
28. Ford HE, Marshall A, Bridgewater JA, et al; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15(1):78-86.
29. Fuchs CS, Tomasek J, Yong CJ, et al; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD). Lancet. 2014;383(9911):31-39.
30. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31(35):4438-4444.
31. Wilke H, Muro K, Van Cutsem E, et al; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-1235.
32. Chan WL, Yuen KK, Siu SW, Lam KO, Kwong DL. Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;116:68-81.
33. Le DT, Bendell JC, Calvo E, et al Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): results from the CheckMate-032 study. J Clin Oncol. 2016;34(suppl 4):6. doi:10.1200/jco.2016.34.4_suppl.6
34. Kojima T, Hara H, Yamaguchi K, et al Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: preliminary report of overall survival. J Clin Oncol. 2016;34(suppl 4):TPS175. doi:10.1200/jco.2016.34.4_suppl.tps175
35. Chung HC, Arkenau HT, Wyrwicz L, et al Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer. J Clin Oncol. 2016;34(suppl 4):167.doi:10.1200/jco.2016.34.4_suppl.167
36. Segal NH, Hamid O, Hwu W, et al. A phase I multi-arm dose-expansion study of the anti-programmed cell death-ligand-1 (PD-L1) antibody media4736: preliminary data. Ann Oncol. 2014;25(suppl 4):iv365.
37. Kang KY, Satoh T, Ryu MS, et al Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): a double-blinded, randomized, phase III trial. J Clin Oncol. 2017;35(suppl 4):2. doi:10.1200/JCO.2017.35.4_suppl.2
38. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Lancet. 2017;390(10111):2461-2471.
39. Derks S, Liao X, Chiaravalli AM, et al. Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers. Oncotarget. 2016;7(22):32925-32932.
40. National Institutes of Health. A study of pembrolizumab (MK-3475) versus paclitaxel for participants with advanced gastric/gastroesophageal junction adenocarcinoma that progressed after therapy with platinum and fluoropyrimidine (MK-3475-061/KEYNOTE-061). https://clinicaltrials.gov/ct2/show/NCT02370498. Accessed December 5, 2017.
41. National Institutes of Health. Study of pembrolizumab (MK-3475) as first-line monotherapy and combination therapy for treatment of advanced gastric or gastroesophageal junction adenocarcinoma (MK-3475-062/KEYNOTE-062). https://clinicaltrials.gov/ct2/show/NCT02494583. Accessed December 5, 2017.